Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Suzanne Cohen

Dermatology Rutherford, NJ Physician Assistant

NPI 1780014571 CMS profile 11224767

75 Orient Way Ste 204, Rutherford, NJ 07070

Open in the dashboard

General payments

$4,634

268 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Suzanne Cohen of Rutherford, NJ is reported in the CMS Open Payments database as having received $4,634 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $526 17
2024 General $405 14
2023 General $1,423 91
2022 General $1,326 104
2021 General $954 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suzanne Cohen
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Suzanne Cohen were reported at $526. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Suzanne Cohen Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $954 $377 $108–$1,108 $132
2022 $1,326 $514 $143–$1,391 $149
2023 $1,423 $607 $159–$1,674 $160
2024 $405 $751 $204–$1,903 $164
2025 $526 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,500 78 payments
  2. Janssen Biotech, Inc. $664 50 payments
  3. Lilly USA, LLC $607 43 payments
  4. Genzyme Corporation $262 10 payments
  5. Regeneron Healthcare Solutions, Inc. $217 10 payments
  6. Novartis Pharmaceuticals Corporation $217 12 payments
  7. Incyte Corporation $203 14 payments
  8. Pfizer Inc. $125 7 payments
  9. Janssen Scientific Affairs, LLC $125 1 payment
  10. Galderma Laboratories, L.P. $118 4 payments
  11. Other $595 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,294 264 payments
  2. Education $340 4 payments
Products named General payments · program years 2021–2025
  1. TALTZ $607 43 payments
  2. TREMFYA $520 27 payments
  3. BOTOX $390 11 payments
  4. DUPIXENT $384 11 payments
  5. SKYRIZI $339 33 payments
  6. SIMPONI ARIA $269 24 payments
  7. STELARA $269 24 payments
  8. REMICADE $269 24 payments
  9. SIMPONI $269 24 payments
  10. RINVOQ $223 20 payments
  11. Other $1,694 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record